profit from every $100 of sales.
$0$100
Embecta
$6.43-1.53% today
-55.7% in 1 year
1-year low $2.901-year high $14.64
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $3.82 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Embecta sold, what it kept, and what it did with the cash.
Sales went from $1.13 billion in 2022 to $1.08 billion in 2025, with $95.4 million of profit last year.
SalesProfit
Embecta handed back 19% of the cash it generated last year.
$35M
Free cash flow 2025$182M
Bought back its own shares–
Paid as dividends$35M
Cash vs. debt$226M vs. $1.4B
Embecta vs. similar companies
Embecta grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Embecta | 3.8× · Cheap | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Embecta's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,130 | 1,121 | 1,123 | 1,080 | |
| 775 | 750 | 735 | 677 | |
| 369 | 224 | 285 | 296 | |
| 335 | 245 | 193 | 284 | |
| 224 | 70 | 78 | 95 | |
| 3.89 | 1.22 | 1.34 | 1.62 | |
| 68.6% | 66.9% | 65.5% | 62.6% | |
| 32.6% | 20.0% | 25.4% | 27.4% | |
| 19.8% | 6.3% | 7.0% | 8.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,086 | 1,214 | 1,285 | 1,091 |
| Cash | 331 | 326 | 268 | 226 |
| Total debt | 1,644 | 1,639 | 1,608 | 1,430 |
| Total liabilities | 1,978 | 2,036 | 2,024 | 1,742 |
| -891 | -822 | -739 | -651 | |
| 57 | 58 | 58 | 59 | |
| 31.8% | 20.6% | 14.2% | 24.7% | |
| -25.1% | -8.6% | -10.6% | -14.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 412 | 68 | 36 | 192 | |
| 24 | 27 | 16 | 9 | |
| 388 | 41 | 20 | 182 | |
| Dividends paid | 9 | 34 | 35 | 35 |
| – | – | – | – | |
| 19 | 22 | 26 | 32 |
Valuation
- 3.8×
- 2.3×
- –
- -0.3×
- 0.3×
- 2.0×
- 5.5×
- 50.1%
- 26.2%
- 20.7%
Profitability
- 62.6%
- 27.4%
- 8.8%
- 31.9%
- 25.8%
- 25.9%
- -17.5%
- 10.9%
- 39.7%
- 1.8%
Growth
- −1.5%
- −25.3%
- +816.6%
- –
- +0.7%
Financial health
- 3.5×
- -2.17
- 131.9%
- 3.1×
- 2.46
- 1.68
- 1.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 5%of 952
Top 12%of 883
Top 2%of 576
Bottom 13%of 870
Top 1%of 985
What analysts expect
- Average price target
- $12.00
- Range
- $12.00 – $12.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.27 | 0.42 | −35.7% |
| Feb 5, 2026 | 0.71 | 0.67 | +6.0% |
| Nov 25, 2025 | 0.50 | 0.70 | −28.6% |
| Aug 8, 2025 | 1.12 | 0.46 | +146.2% |
| May 9, 2025 | 0.70 | 0.66 | +6.1% |
| Feb 6, 2025 | 0.65 | 0.45 | +44.4% |
| Nov 26, 2024 | 0.45 | 0.36 | +25.0% |
| Aug 9, 2024 | 0.74 | 0.48 | +54.2% |
20.7%of the share price, paid each year
On $1,000 invested$207a year at today's yield, before tax
–per share
Raised–not every year
Paid per share, each year
$0.30 in 2022 → $0.60 in 2025
How safe it looks
36.7% of its profit
Room to growStretchedMore than it earns: 19.2%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
79Pass
Benjamin Graham
100Pass
Philip Fisher
64Pass
Peter Lynch
16No pass
Joel Greenblatt
82Pass
Charlie Munger
72Pass
Terry Smith
69Pass
Questions about Embecta
Is Embecta a good stock to buy?
A business with weak numbers, and the price looks low. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Embecta AI analysis
What does Embecta do?
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. It is in Drug Manufacturers - Specialty & Generic.
Does Embecta pay a dividend?
Yes. At today's price the dividend is 20.7% a year, about 37% of its yearly profit. In 2025 it paid out $35.0 million in dividends.
Is Embecta stock halal?
No. Embecta does not pass our halal screen: its debt is 393% of its market value, at or above the 33% limit. How we check
How has Embecta stock done over the past year?
Down 55.7% over the past twelve months, to $6.43. It traded between $2.90 and $14.64 and is 56.1% below its high.
Who are Embecta's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Embecta's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.